“Our research demonstrates a broad principle that may change the way we think about treatment-resistant cancer,” Samuels says. “The same mutations that allow a tumor to evade a drug can, through precise immunotherapy, become the cancer’s weak point. Unlike ‘boutique’ immunotherapies that must be tailored to each individual patient, these therapies could be suitable for large groups of patients.”
Science Stories
Instead of Fighting Cancer Resistance, Put It to Work
Three resistance mutations identified in Prof. Yardena Samuels’s lab may become targets for powerful new immunotherapies
One of the most challenging moments in cancer treatment comes when a therapy stops working. In many metastatic cancers, drugs that are initially effective lose their potency over time, as malignant cells acquire mutations that enable them to survive and spread. A new study from Prof. Yardena Samuels’s lab at the Weizmann Institute of Science proposes a new way to confront cancer resistance: harnessing the very mutations that make tumors resistant in order to fight the cancer.
(l-r) Prof. Yardena Samuels, Dr. Shira Sagie and Dr. Nofar Gumpert
“The same mutations that allow a tumor to evade a drug can become the cancer’s weak point”
—
As a test case, the team, led by Drs. Nofar Gumpert and Shira Sagie of Samuels’s lab, focused on metastatic prostate cancer, a disease in which most patients eventually develop resistance to existing therapies. In collaboration with Sheba Medical Center and Hadassah Medical Center in Israel, as well as medical centers and universities in North America and Europe, the researchers identified three neo-antigens that showed promising results in laboratory experiments and in mouse models of cancer. These findings may pave the way for the development of new immunotherapies for treatment-resistant prostate cancer.
Prof. Yardena Samuels’s research is supported by the Moross Integrated Cancer Center; the Dwek Institute for Cancer Therapy Research; the EKARD Institute for Cancer Diagnosis Research; the Weizmann-Brazil Tumor Bank; the M.E.H Fund – in the name of Margot and Ernst Hamburger; and the Jean Jacques Roboh Cancer Research Collaboration Fund.
Prof. Samuels is the incumbent of the Knell Family Professorial Chair.
Related Stories
Science Stories
Not every DNA mistake gets fixed. Researchers uncover how repair enzymes choose which genetic damage deserves attention
Science Stories, Women for Science
The blockbuster drug may strengthen a newly discovered cholesterol-regulating mechanism that could be harnessed to curb cancer spread
Science Stories
Weizmann Institute researchers discover immune memory cells capable of producing antibodies against cancer – a finding that opens new avenues for future cancer vaccines
